First Study to Explore a Treat-to-Target Strategy in Crohn’s Disease using Endoscopy to Guide Dose Adjustment First Study to Evaluate Intestinal Ultrasound Monitoring in an Interventional Setting VIENNA–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies...
WAKEFIELD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) –Innovation Pharma (Formerly known as Cellceutix) (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that preliminary top-line data from its Phase 1 trial (NCT03234465)...
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response,...
EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two...
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monitoring Board has...
Following this clearance, SARA-INT trial to recruit 231 patients vs. 334 initially planned More than 80% of patients are now recruited – completion of patient recruitment expected in Q2 2020 Interim analysis by the study’s data safety and monitoring board (DSMB)...
Email
Text